<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: government regulatory approval", fill: "#faebd7"},
{source: "3: government regulatory approval", target: "3: cannot sell", fill: "#faebd7"},
{source: "3: cannot sell", target: "3: generate revenues", fill: "#faebd7"},
{source: "3: government regulatory approval", target: "4: principal development efforts", fill: "#d71868"},
{source: "4: principal development efforts", target: "4: currently centered around immune", fill: "#d71868"},
{source: "4: currently centered around immune", target: "4: regulating hormones", fill: "#d71868"},
{source: "4: regulating hormones", target: "4: drug candidates which", fill: "#d71868"},
{source: "4: drug candidates which", target: "4: appropriate immune response", fill: "#d71868"},
{source: "4: principal development efforts", target: "5: drug candidates", fill: "#3b3c36"},
{source: "5: drug candidates", target: "5: approval by", fill: "#3b3c36"},
{source: "5: approval by", target: "5: commercialized", fill: "#3b3c36"},
{source: "5: commercialized", target: "5: well as approval by various foreign government agencies", fill: "#3b3c36"},
{source: "5: drug candidates", target: "7: candidates", fill: "#483d8b"},
{source: "7: candidates", target: "14: Contents ", fill: "#6f4e37"},
{source: "14: Contents ", target: "14: regulatory authorities", fill: "#6f4e37"},
{source: "14: regulatory authorities", target: "14: partner conducting research", fill: "#6f4e37"},
{source: "14: partner conducting research", target: "14: development", fill: "#6f4e37"},
{source: "14: development", target: "14: complied with regulations", fill: "#6f4e37"},
{source: "14: complied with regulations", target: "14: drug candidate", fill: "#6f4e37"},
{source: "14: drug candidate", target: "14: drug candidates then", fill: "#6f4e37"},
{source: "14: Contents ", target: "58: In February ", fill: "#8601af"},
{source: "58: In February ", target: "58: common stock", fill: "#8601af"},
{source: "58: common stock", target: "58: purchase common stock pursuant", fill: "#8601af"},
{source: "58: In February ", target: "START_HERE", fill: "#8601af"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_discovery">Drug discovery</a></td>
      <td>In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.Historically, drugs were discovered by identifying the active ingredient from traditional remedies or by serendipitous discovery, as with penicillin. More recently, chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that had a desirable therapeutic effect in a process known as classical pharmacology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mirati_Therapeutics">Mirati Therapeutics</a></td>
      <td>Mirati Therapeutics is an American targeted oncology company that focuses on the development of cancer therapeutics.\n\n\n== History ==\nMirati Therapeutics works largely in KRAS-mutation inhibition, and developing treatments for tumors that contain it.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_development">Drug development</a></td>
      <td>Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery.  It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_metabolism">Drug metabolism</a></td>
      <td>Drug metabolism is the metabolic breakdown of drugs by living organisms, usually through specialized enzymatic systems. More generally, xenobiotic metabolism (from the Greek xenos "stranger"  and biotic "related to living beings") is the set of metabolic pathways that modify the chemical structure of xenobiotics, which are compounds foreign to an organism's normal biochemistry, such as any drug or poison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Santaris_Pharma">Santaris Pharma</a></td>
      <td>Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen, Denmark. The company also had a branch in San Diego, California that opened in 2009.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/COVID-19_drug_development">COVID-19 drug development</a></td>
      <td>COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research (506 total candidates in April 2021), with 419 potential COVID-19 drugs in clinical trials, as of April 2021.As early as March 2020, the World Health Organization (WHO), European Medicines Agency (EMA), US Food and Drug Administration (FDA), and the Chinese government and drug manufacturers were coordinating with academic and industry researchers to speed development of vaccines, antiviral drugs, and post-infection therapies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidate">Candidate</a></td>
      <td>A candidate, or nominee, is the prospective recipient of an award or honor, or a person seeking or being considered for some kind of position; for example:\n\nto be elected to an office — in this case a candidate selection procedure occurs.\nto receive membership in a  group"Nomination" is part of the process of selecting a candidate for either election to an office by a political party, or the bestowing of an honor or award.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_of_the_2022_Australian_federal_election">Candidates of the 2022 Australian federal election</a></td>
      <td>This is a list of confirmed candidates in ballot paper order for the 2022 Australian federal election.At the close of nominations a total of 1,624 candidates had stood for election, of whom 1,203 were House of Representatives candidates and 421 were Senate candidates.\n\n\n== Retiring members ==\nThe seat of Spence (SA) was vacant following the resignation of Nick Champion (Labor) on 22 February 2022 to contest the South Australian state election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Write-in_candidate">Write-in candidate</a></td>
      <td>A write-in candidate is a candidate whose name does not appear on the ballot but seeks election by asking voters to cast a vote for the candidate by physically writing in the person's name on the ballot. Depending on electoral law it may be possible to win an election by winning a sufficient number of such write-in votes, which count equally as if the person was formally listed on the ballot.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, to decide the challenger for the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2022_Lebanese_general_election">2022 Lebanese general election</a></td>
      <td>General elections were held in Lebanon on 15 May 2022. The country has for several years been the subject of chronic political instability as well as a serious economic crisis aggravated by the 2020 explosions that hit the Port of Beirut and faced large-scale demonstrations against the political class.Hezbollah and their allies lost their parliamentary majority but still won the Parliament speaker election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Officer_candidate">Officer candidate</a></td>
      <td>Officer candidate or officer aspirant (OA) is a rank in some militaries of the world that is an appointed position while a person is in training to become an officer.  More often than not, an officer candidate was a civilian who applied to join the military directly as an officer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>HOLLIS EDEN PHARMACEUTICALS INC /DE/      Item 1A Risk Factors          In evaluating our business, you should consider the following discussion of     risks, in addition to other information contained in this report as well as     our other <font color="blue">public filings with</font> the <font color="blue">Securities and Exchange Commission</font></td>
    </tr>
    <tr>
      <td>Any of     the  following  risks  could <font color="blue">materially</font> <font color="blue">adversely</font> affect our business,     <font color="blue">financial condition</font>, results of <font color="blue">operations</font> and prospects</td>
    </tr>
    <tr>
      <td>If we do not obtain <font color="blue"><font color="blue">government</font> <font color="blue">regulatory</font> approval</font> for our products, we     <font color="blue">cannot sell</font> our products and we will not <font color="blue">generate revenues</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">principal <font color="blue">development</font> efforts</font> are <font color="blue">currently centered around immune</font>     <font color="blue">regulating hormones</font>, a class of <font color="blue"><font color="blue">drug <font color="blue">candidates</font></font> which</font> we believe shows     promise for the treatment of diseases and disorders in which the body is     unable to mount an <font color="blue">appropriate immune response</font></td>
    </tr>
    <tr>
      <td>However, all <font color="blue">drug <font color="blue">candidates</font></font>     require <font color="blue">approval by</font> the FDA before they can be <font color="blue"><font color="blue">commercialize</font>d</font> in the US as     well as <font color="blue">approval by</font> various foreign <font color="blue">government</font> agencies before they can     <font color="blue"><font color="blue">commercialize</font>d</font> in other countries</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> change from time to     time and new <font color="blue">regulations</font> may be adopted</td>
    </tr>
    <tr>
      <td>None of our <font color="blue">drug <font color="blue">candidates</font></font> have     been approved for commercial sale</td>
    </tr>
    <tr>
      <td>We <font color="blue">may incur <font color="blue">significant</font> <font color="blue">additional</font></font>     operating  losses  for  the <font color="blue">foreseeable future as</font> we <font color="blue">fund <font color="blue">development</font></font>,     preclinical and <font color="blue">clinical testing</font> and other expenses in support of <font color="blue">regulatory</font>     approval of our <font color="blue">drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>While limited <font color="blue">clinical trials</font> of our drug     <font color="blue">candidates</font> have been conducted to date, <font color="blue">significant</font> <font color="blue">additional</font> trials are     required, and we may not be able to <font color="blue">demonstrate</font> that these <font color="blue">drug <font color="blue">candidates</font></font>     are  safe or <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">demonstrate</font> the safety and     <font color="blue">effective</font>ness  of  a  <font color="blue">particular <font color="blue">drug candidate</font></font> to the <font color="blue">satisfaction</font> of     <font color="blue">regulatory</font>  <font color="blue">authorities</font>,  the  <font color="blue"><font color="blue">drug candidate</font> will</font> not obtain required     <font color="blue"><font color="blue">government</font> approval</font></td>
    </tr>
    <tr>
      <td>If we do not receive FDA or foreign approvals for our     <font color="blue">drug <font color="blue">candidates</font></font>, we will not be able to sell products and will not generate     revenues</td>
    </tr>
    <tr>
      <td>If we receive <font color="blue">regulatory</font> approval of one of our <font color="blue">drug <font color="blue">candidates</font></font>,     <font color="blue">such approval may impose limitations on</font> the <font color="blue">indicated uses</font> for which we may     market  the resulting product, which may limit our ability to generate     <font color="blue"><font color="blue">significant</font> revenues</font></td>
    </tr>
    <tr>
      <td>Further, US or foreign <font color="blue">regulatory</font> agencies could     change existing, or promulgate new, <font color="blue">regulations</font> at any time which may affect     our ability to obtain approval of our <font color="blue">drug <font color="blue">candidates</font></font> or require <font color="blue">significant</font>     <font color="blue">additional</font> costs to obtain such approvals</td>
    </tr>
    <tr>
      <td>In addition, if                                           19     ______________________________________________________________________    [45]Table of <font color="blue">Contents       </font><font color="blue">regulatory</font> <font color="blue">authorities</font> determine that we or a <font color="blue">partner conducting research</font>     and <font color="blue">development</font> activities on our behalf have not complied with <font color="blue">regulations</font>     in the research and <font color="blue">development</font> of one of our <font color="blue">drug <font color="blue">candidates</font></font>, then they may     not approve the <font color="blue">drug candidate</font> and we will not be able to market and sell     it</td>
    </tr>
    <tr>
      <td>If we were unable to market and sell our <font color="blue">drug <font color="blue">candidates</font></font>, our business     and results of <font color="blue">operations</font> would be <font color="blue">materially</font> and <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>If we do not <font color="blue"><font color="blue">successfully</font> <font color="blue">commercialize</font></font> our products, we may never achieve     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We have experienced <font color="blue">significant</font> operating losses to date because of the     substantial expenses we have incurred to acquire and <font color="blue">fund <font color="blue">development</font></font> of our     drug  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We have never had operating revenues and have never     <font color="blue"><font color="blue">commercially</font> introduced</font> a product</td>
    </tr>
    <tr>
      <td>Our <font color="blue">accumulated deficit</font> was <font color="blue">approximately</font>     dlra161dtta3 million as of <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Our net losses for <font color="blue">fiscal years</font>     2005, 2004 and 2003 were <font color="blue">approximately</font> dlra29dtta4 million, dlra24dtta8 million and     dlra25dtta7 million, respectively</td>
    </tr>
    <tr>
      <td>Many of our research and <font color="blue">development</font> programs     are at an early stage</td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font><font color="blue">drug <font color="blue">candidates</font></font> are subject to inherent     risks  of  failure</td>
    </tr>
    <tr>
      <td>These risks include the <font color="blue">possibilities</font> that no drug     candidate  will be found safe or <font color="blue">effective</font>, meet applicable <font color="blue">regulatory</font>     standards or receive the <font color="blue">necessary</font> <font color="blue">regulatory</font> clearances</td>
    </tr>
    <tr>
      <td>Even safe and     <font color="blue">effective</font>  drug  <font color="blue">candidates</font>  may  never be developed <font color="blue">into <font color="blue">commercially</font></font>     <font color="blue">successful drugs</font></td>
    </tr>
    <tr>
      <td>If we are unable to develop safe, <font color="blue">commercially</font> viable     drugs, we may never achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">become profitable</font>, we may     not <font color="blue">remain profitable</font></td>
    </tr>
    <tr>
      <td>The market for treating <font color="blue">Acute Radiation Syndrome </font>is uncertain</td>
    </tr>
    <tr>
      <td>We do not believe any drug has <font color="blue">ever been approved</font> and <font color="blue"><font color="blue">commercialize</font>d</font> for the     treatment of <font color="blue">severe acute radiation injury</font></td>
    </tr>
    <tr>
      <td>In addition, the incidence of     large-scale  exposure  to nuclear or <font color="blue">radiological events</font> has been low</td>
    </tr>
    <tr>
      <td>Accordingly,  even  if NEUMUNE, our lead <font color="blue">drug candidate</font> to treat Acute     Radiation Syndrome (ARS), is <font color="blue">approved by</font> the FDA, we <font color="blue"><font color="blue">cannot predict</font> with</font> any     <font color="blue">certainty</font> the size of this market</td>
    </tr>
    <tr>
      <td>The <font color="blue">potential market</font> for NEUMUNE is     <font color="blue">largely dependent on</font> the size of <font color="blue">stockpiling orders</font>, if any, <font color="blue">procured by</font>     <font color="blue">government</font>  agencies</td>
    </tr>
    <tr>
      <td>While a number of <font color="blue">government</font>s have <font color="blue">historically</font>     stockpiled drugs to treat <font color="blue">indications</font> such as smallpox, anthrax exposure,     plague, tularemia and certain long-term effects of radiation exposure, we     are unaware of any <font color="blue">significant</font> <font color="blue">stockpiling orders</font> for drugs to treat ARS On     <font color="blue">December </font>9, 2005, the US Department of Health and Human Services (DHHS)     issued a Request for Proposal (RFP) <font color="blue">which specified</font> an <font color="blue">initial potential</font>     stockpiling  order  of  up  to  100cmam000  treatment  regimens, which is     <font color="blue">substantially lower than</font> we had anticipated</td>
    </tr>
    <tr>
      <td>While we have responded to the     RFP, we <font color="blue">cannot guarantee</font> that we will be able to meet the <font color="blue">requirements set</font>     forth in the RFP or that we will receive any resulting <font color="blue">stockpiling orders</font></td>
    </tr>
    <tr>
      <td>A     <font color="blue">decision by</font> any department of the <font color="blue">US Government </font>to <font color="blue">enter into</font> a <font color="blue">commitment</font>     to purchase NEUMUNE, whether before or after FDA approval, is <font color="blue">largely out</font> of     our control</td>
    </tr>
    <tr>
      <td>Our <font color="blue">development</font> plans and <font color="blue">timelines may vary substantially</font>     <font color="blue">depending on whether</font> we receive such a <font color="blue">commitment</font> and the size of such     <font color="blue">commitment</font>, if any</td>
    </tr>
    <tr>
      <td>In addition, even if NEUMUNE is <font color="blue">approved by</font> <font color="blue">regulatory</font>     <font color="blue">authorities</font>, we <font color="blue">cannot guarantee</font> that we will receive any <font color="blue">stockpiling orders</font>     for NEUMUNE, that any such order would be profitable to us or that <font color="blue">NEUMUNE     </font>will achieve <font color="blue">market acceptance by</font> the <font color="blue">general public</font></td>
    </tr>
    <tr>
      <td>As a result of our intensely <font color="blue">competitive</font> industry, we may not gain enough     market share to be profitable</td>
    </tr>
    <tr>
      <td>The <font color="blue">bio<font color="blue">technology</font></font> and <font color="blue"><font color="blue">pharmaceutical</font> industries</font> are intensely <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">numerous <font color="blue">competitors</font></font> in the US and elsewhere</td>
    </tr>
    <tr>
      <td>Because we are     pursuing  <font color="blue">potentially</font>  large  markets,  our  <font color="blue">competitors</font> include major     multinational <font color="blue">pharmaceutical</font> companies, specialized <font color="blue">bio<font color="blue">technology</font></font> firms and     <font color="blue">universities</font> and other <font color="blue">research <font color="blue">institutions</font></font></td>
    </tr>
    <tr>
      <td>Several of these entities have     already <font color="blue">successfully</font> marketed and <font color="blue"><font color="blue">commercialize</font>d</font> products that will compete     with our products, assuming that our products gain <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>such as Amgen Inc</td>
    </tr>
    <tr>
      <td>have developed or are developing products to     <font color="blue">boost neutrophils</font> after <font color="blue">chemotherapy</font></td>
    </tr>
    <tr>
      <td>are also     developing and <font color="blue">marketing new drugs</font> for the treatment of <font color="blue">chronic inflammatory</font>     <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>such as GlaxoSmithKline, Merck &amp; Company, Roche     Pharmaceuticals, Pfizer Inc</td>
    </tr>
    <tr>
      <td>and <font color="blue">Abbott Laboratories </font>have <font color="blue">significant</font> market     share for the treatment of a number of infectious diseases such as <font color="blue">HIV In     </font>addition, <font color="blue">bio<font color="blue">technology</font></font> companies such as Gilead Sciences Inc, Chiron     Corporation and Vertex Pharmaceuticals Inc, as well as many others, have     <font color="blue">marketed products</font> or research and <font color="blue">development</font> programs in these fields</td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________    [46]Table of <font color="blue">Contents       </font>Many of these <font color="blue">competitors</font> have greater financial and other resources, larger     research  and  <font color="blue">development</font>  staffs  and  more  <font color="blue">effective</font> marketing and     <font color="blue"><font color="blue">manufacturing</font> <font color="blue">organizations</font> than</font> we do</td>
    </tr>
    <tr>
      <td>In addition, academic and <font color="blue">government</font>     <font color="blue">institutions</font> have <font color="blue">become increasingly aware</font> of the <font color="blue">commercial value</font> of their     <font color="blue">research findings</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">institutions</font> are now more likely to <font color="blue">enter into</font>     exclusive licensing agreements with commercial enterprises, including our     <font color="blue">competitors</font>, to develop and <font color="blue">market commercial products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may succeed in developing or <font color="blue">licensing <font color="blue">technologies</font></font> and     drugs that are more <font color="blue">effective</font> or <font color="blue">less costly than</font> any we are developing</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">competitors</font> may succeed in obtaining FDA or other <font color="blue">regulatory</font> approvals for     <font color="blue">drug <font color="blue">candidates</font></font> before we do</td>
    </tr>
    <tr>
      <td>If competing <font color="blue">drug <font color="blue">candidates</font></font> prove to be more     <font color="blue">effective</font> or <font color="blue">less costly than</font> our <font color="blue">drug <font color="blue">candidates</font></font>, our <font color="blue">drug <font color="blue">candidates</font></font>, even     if approved for sale, may not be able to compete <font color="blue">successfully</font> with our     <font color="blue">competitors</font>’ existing products or new products under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>If we are     unable to compete <font color="blue">successfully</font>, we may never be able to <font color="blue">sell enough products</font>     at a <font color="blue">price sufficient</font> to <font color="blue">permit us</font> to <font color="blue">generate profits</font></td>
    </tr>
    <tr>
      <td>We may need to raise <font color="blue">additional</font> money before we achieve <font color="blue">profitability</font>; if we     fail  to raise <font color="blue">additional</font> money, it could be <font color="blue">difficult</font> to continue our     business</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, our cash and cash <font color="blue">equivalents</font> totaled <font color="blue">approximately</font>     dlra45dtta1 million</td>
    </tr>
    <tr>
      <td><font color="blue">In February </font>2006, we completed an offering of <font color="blue">common stock</font>     and warrants to purchase <font color="blue">common stock</font>, pursuant to which we received net     proceeds of <font color="blue">approximately</font> dlra24dtta4 million</td>
    </tr>
    <tr>
      <td>Based on our current plans, we     believe these <font color="blue">financial resources</font>, and interest earned thereon, will be     sufficient to meet our operating expenses and <font color="blue">capital requirements</font> for at     least the next 12 months</td>
    </tr>
    <tr>
      <td>However, changes in our research and <font color="blue">development</font>     plans or other <font color="blue">events affecting</font> our operating <font color="blue">expenses may</font> result in the     <font color="blue">expenditure</font>  of such cash before that time</td>
    </tr>
    <tr>
      <td>We may require substantial     <font color="blue">additional</font> funds in order to finance our <font color="blue">drug discovery</font> and <font color="blue">development</font>     programs, fund operating expenses, pursue <font color="blue">regulatory</font> clearances, develop     <font color="blue">manufacturing</font>, marketing and <font color="blue">sales capabilities</font>, and prosecute and defend     our <font color="blue">intellectual property rights</font></td>
    </tr>
    <tr>
      <td>We may seek <font color="blue">additional</font> funding through     public or <font color="blue">private financing</font> or <font color="blue">through collaborative arrangements with</font>     <font color="blue">strategic partners</font></td>
    </tr>
    <tr>
      <td>You should be aware that in the future:           •   we may not obtain <font color="blue">additional</font> <font color="blue">financial resources</font> when <font color="blue">necessary</font> or on     terms favorable to us, if at all; and           •   any available <font color="blue">additional</font> financing may not be adequate</td>
    </tr>
    <tr>
      <td>If we cannot raise <font color="blue">additional</font> funds when needed, or on acceptable terms, we     will not be able to continue to develop our <font color="blue">drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Failure to protect our <font color="blue">proprietary</font> <font color="blue">technology</font> could impair our <font color="blue">competitive</font>     position</td>
    </tr>
    <tr>
      <td>We own or have obtained a license to numerous US and foreign patents and     foreign patent <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in part on our ability to     obtain and <font color="blue">defend <font color="blue">patent rights</font></font> and other <font color="blue">intellectual property rights</font> that     are  important to our ability to <font color="blue">commercialize</font> our <font color="blue">drug <font color="blue">candidates</font></font>, if     approved and our ability to operate our business <font color="blue">without infringing</font> the     <font color="blue">proprietary</font> rights of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We place considerable <font color="blue">importance on</font>     obtaining <font color="blue">patent protection</font> for <font color="blue">significant</font> new <font color="blue">technologies</font>, products and     processes</td>
    </tr>
    <tr>
      <td>Legal standards relating to the validity of <font color="blue">patents covering</font>     <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> <font color="blue">inventions</font> and the scope of claims made     <font color="blue">under such patents</font> are still developing</td>
    </tr>
    <tr>
      <td>In some of the countries in which     we intend to market our <font color="blue">drug <font color="blue">candidates</font></font>, if approved, <font color="blue">pharmaceutical</font>s are     either  not  patentable  or have <font color="blue">only recently become patentable</font></td>
    </tr>
    <tr>
      <td><font color="blue">Past     </font><font color="blue">enforcement</font> of <font color="blue">intellectual property rights</font> in many of these countries has     been limited or non-existent</td>
    </tr>
    <tr>
      <td>Future <font color="blue">enforcement</font> of patents and <font color="blue">proprietary</font>     rights  in  many  other <font color="blue">countries may</font> be problematic or unpredictable</td>
    </tr>
    <tr>
      <td>Moreover,  the issuance of a patent in <font color="blue">one country</font> does not assure the     issuance of a similar patent in another country</td>
    </tr>
    <tr>
      <td>Claim interpretation and     <font color="blue">infringement laws vary by nation</font>, so the extent of any <font color="blue">patent protection</font> is     uncertain and may vary in <font color="blue">different jurisdictions</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">domestic patent</font>     position is <font color="blue">also highly uncertain</font> and <font color="blue">involves complex legal</font>                                           21     ______________________________________________________________________    [47]Table of <font color="blue">Contents       </font>and factual questions</td>
    </tr>
    <tr>
      <td>The applicant or inventors of subject matter covered     by patent <font color="blue">applications</font> or patents owned by or licensed to us may not have     been the first to invent or the first to file patent <font color="blue">applications</font> for such     <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>Due to <font color="blue">uncertainties</font> regarding patent law and the <font color="blue">circumstances</font>     surrounding  our  patent  <font color="blue">applications</font>,  the  pending or <font color="blue">future patent</font>     <font color="blue">applications</font> we own or have <font color="blue">licensed may</font> not result in the issuance of any     patents</td>
    </tr>
    <tr>
      <td>Existing or <font color="blue">future patent</font>s owned by or licensed to us may be     challenged,  infringed upon, invalidated, found to be unenforceable or     <font color="blue">circumvented</font> by others</td>
    </tr>
    <tr>
      <td>Further, any rights we may have under any issued     patents  may not provide us with sufficient protection against similar     <font color="blue">competitive</font> products or <font color="blue">technologies</font> that do not infringe on patents or     otherwise cover <font color="blue">commercially</font> valuable products or processes</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>or other disputes regarding patents and other <font color="blue">proprietary</font> rights     may be expensive, cause delays in <font color="blue">bringing products</font> to market and harm our     ability to operate</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font>, use or sale of our <font color="blue">drug <font color="blue">candidates</font></font> may infringe on the     <font color="blue">patent rights</font> of others</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">avoid infringement</font> of the     <font color="blue">patent rights</font> of others, we may be required to seek a license, defend an     <font color="blue">infringement action</font> or challenge the validity of the patents in court</td>
    </tr>
    <tr>
      <td>Patent <font color="blue">litigation</font> is costly and time consuming and can preclude, delay or     <font color="blue">suspend commercialization</font> of products</td>
    </tr>
    <tr>
      <td>We may not have <font color="blue">sufficient resources</font>     to bring these actions to a <font color="blue">successful conclusion</font></td>
    </tr>
    <tr>
      <td>In addition, if we do not     obtain a license, develop or obtain non-infringing <font color="blue">technology</font>, or fail to     <font color="blue">successfully</font>  defend an <font color="blue">infringement action</font> or have the patents we are     alleged to infringe declared invalid, we may:           •   incur substantial <font color="blue">money damages</font>;           •   encounter <font color="blue">significant</font> delays in bringing our <font color="blue">drug <font color="blue">candidates</font></font> to     market;           •   be <font color="blue">precluded from <font color="blue">participating</font></font> in the <font color="blue">manufacture</font>, use or sale of our     <font color="blue">drug <font color="blue">candidates</font></font> or methods of <font color="blue">treatment without first</font> obtaining licenses to     do so; and/or           •   not be able to obtain any required <font color="blue">license on</font> favorable terms, if at     all</td>
    </tr>
    <tr>
      <td>In addition, if another party claims the same subject matter or subject     matter <font color="blue">overlapping with</font> the subject matter that we have claimed in a US     patent application or patent, we may decide or be required to <font color="blue">participate</font> in     <font color="blue"><font color="blue">interference</font> <font color="blue">proceedings</font></font> in the <font color="blue">US Patent and Trademark Office </font>in order to     determine the priority of invention</td>
    </tr>
    <tr>
      <td>Loss of such an <font color="blue">interference</font> proceeding     would deprive us of <font color="blue">patent protection</font> sought or <font color="blue">previously</font> obtained and     could prevent us from <font color="blue">commercializing</font> our products</td>
    </tr>
    <tr>
      <td><font color="blue">Participation </font>in such     <font color="blue">proceedings</font> could result in substantial costs, whether or not the eventual     outcome is favorable</td>
    </tr>
    <tr>
      <td>These <font color="blue">additional</font> costs could <font color="blue">adversely</font> affect our     financial results</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>may be expensive and time consuming and may <font color="blue">adversely</font> affect our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>From time to time, we may be involved in <font color="blue">litigation</font> relating to claims     arising  out  of  our  <font color="blue">operations</font>  in  the  <font color="blue">normal course</font> of business</td>
    </tr>
    <tr>
      <td><font color="blue">Participation </font>in such <font color="blue">proceedings</font> is time consuming and could result in     substantial costs, whether or not the eventual outcome is favorable</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">additional</font> costs could <font color="blue">adversely</font> affect our financial results</td>
    </tr>
    <tr>
      <td><font color="blue">Confidentiality </font><font color="blue">agreements with employees</font> and others may not <font color="blue">adequately</font>     <font color="blue">prevent disclosure</font> of <font color="blue">trade secrets</font> and other <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>In order to protect our <font color="blue">proprietary</font> <font color="blue">technology</font> and processes, we also rely     in part <font color="blue">on <font color="blue">confidential</font>ity agreements with</font> our employees, consultants,     outside  scientific  <font color="blue">collaborators</font> and <font color="blue">sponsored researchers</font> and other     advisors</td>
    </tr>
    <tr>
      <td>These  <font color="blue">agreements may</font> not <font color="blue">effective</font>ly <font color="blue">prevent disclosure</font> of     <font color="blue">confidential</font> information and may not provide an <font color="blue">adequate remedy</font> in the event     of <font color="blue">unauthorized disclosure</font> of <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>In addition, others     may independently discover <font color="blue">trade secrets</font> and <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td><font color="blue">Costly     </font>and time-consuming <font color="blue">litigation</font> could be <font color="blue">necessary</font> to enforce and determine     the scope of our <font color="blue">proprietary</font> rights, and failure to obtain or maintain trade     secret protection could <font color="blue">adversely</font> affect our <font color="blue">competitive</font> business position</td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________    [48]Table of <font color="blue">Contents       </font>Existing pricing <font color="blue">regulations</font> and <font color="blue">reimbursement limitations may reduce</font> our     <font color="blue">potential <font color="blue">profits from</font></font> the sale of our products</td>
    </tr>
    <tr>
      <td>The requirements governing product licensing, pricing and <font color="blue">reimbursement vary</font>     <font color="blue">widely from country</font> to country</td>
    </tr>
    <tr>
      <td>In many countries, the pricing     <font color="blue">review period begins</font> after product-licensing approval is granted</td>
    </tr>
    <tr>
      <td>As a     result,  we  may  obtain <font color="blue">regulatory</font> approval for a <font color="blue">drug candidate</font> in a     particular country, but then be subject to price <font color="blue">regulations</font> that reduce our     <font color="blue">profits from</font> the sale of the product</td>
    </tr>
    <tr>
      <td>In some <font color="blue">foreign markets pricing</font> of     prescription <font color="blue">pharmaceutical</font>s is subject to continuing <font color="blue">government</font> control     even after <font color="blue">initial marketing approval</font></td>
    </tr>
    <tr>
      <td>In addition, certain <font color="blue">government</font>s may     grant  third  parties a license to <font color="blue">manufacture</font> our <font color="blue">product without</font> our     <font color="blue">permission</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">compulsory licenses may</font> be on terms that are less favorable     to us and <font color="blue">would likely</font> have the effect of reducing our revenues</td>
    </tr>
    <tr>
      <td>Varying <font color="blue">price regulation between countries</font> can lead to <font color="blue">inconsistent prices</font>     and some re-selling by <font color="blue">third parties</font> of products from markets where products     are <font color="blue">sold at lower prices</font> to markets where those products are <font color="blue">sold at higher</font>     prices</td>
    </tr>
    <tr>
      <td>Any practice of exploiting price differences between countries could     undermine our sales in <font color="blue">markets with higher prices</font> and reduce the sales of     our <font color="blue">future products</font>, if any</td>
    </tr>
    <tr>
      <td>While we do not have any <font color="blue">applications</font> for <font color="blue">regulatory</font> approval of our drug     <font color="blue">candidates</font> currently pending, any decline in the size of the markets in     which we may in the <font color="blue">future sell commercial products</font>, assuming our receipt of     the requisite <font color="blue">regulatory</font> approvals, could cause the perceived <font color="blue">market value</font>     of our business and the price of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> our <font color="blue">drug <font color="blue">candidates</font></font> <font color="blue">successfully</font> also will     depend in part on the extent to <font color="blue">which reimbursement</font> for the cost of our drug     <font color="blue">candidates</font> and related <font color="blue">treatments will</font> be available from <font color="blue">government</font> health     <font color="blue">administration</font> <font color="blue">authorities</font>, private health insurers and other <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>Third-party payors are <font color="blue">increasingly challenging</font> the <font color="blue">prices charged</font> for     <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td>If we succeed in bringing any of our drug     <font color="blue">candidates</font> to the market, such <font color="blue">drug <font color="blue">candidates</font></font> may not be considered cost     <font color="blue">effective</font> and <font color="blue">reimbursement may</font> not be available or sufficient to allow us     to sell such <font color="blue">drug <font color="blue">candidates</font></font> on a profitable or <font color="blue">competitive</font> basis</td>
    </tr>
    <tr>
      <td>Delays in the conduct or <font color="blue">completion</font> of our preclinical or <font color="blue">clinical studies</font>     or the analysis of the data from our preclinical or <font color="blue">clinical studies</font> may     result  in  delays in our planned filings for <font color="blue">regulatory</font> approvals, or     <font color="blue">adversely</font> affect our ability to <font color="blue">enter into</font> collaborative arrangements</td>
    </tr>
    <tr>
      <td>The <font color="blue">current status</font> of our <font color="blue">drug <font color="blue">candidates</font></font> is set forth below</td>
    </tr>
    <tr>
      <td>We have either     completed or are in the midst of:           •   <font color="blue">animal efficacy studies with</font> NEUMUNE for the treatment of radiation     exposure;           •   Phase I <font color="blue">clinical trials</font> with <font color="blue">NEUMUNE in the United States </font>and the     Netherlands;           •   <font color="blue">Phase II </font><font color="blue">clinical trials</font> with IMMUNITIN in South Africa and Phase I/II     <font color="blue">clinical trials</font> with IMMUNITIN in the United States for the treatment of     HIV/AIDS; and           •   <font color="blue">Phase II </font><font color="blue">clinical trials</font> with IMMUNITIN in Thailand for the treatment     of malaria         We may encounter problems with some or all of our completed or ongoing     studies that may cause us or <font color="blue">regulatory</font> <font color="blue">authorities</font> to delay or suspend our     <font color="blue">ongoing studies</font> or delay the analysis of data from our completed or ongoing     studies</td>
    </tr>
    <tr>
      <td>We rely, in part, on <font color="blue">third parties</font> to <font color="blue">assist us</font> in managing and     monitoring our preclinical and <font color="blue">clinical studies</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">generally</font> do not have     <font color="blue">control over</font> the amount and timing of resources that our business partners     devote to our <font color="blue">drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on</font> these <font color="blue">third parties</font> may     result in delays in completing or failure to complete studies if third     <font color="blue">parties fail</font> to perform their <font color="blue">obligations</font> to us</td>
    </tr>
    <tr>
      <td>If the results of our     ongoing and planned studies for our <font color="blue">drug <font color="blue">candidates</font></font> are not available when     we expect or if we encounter any delay in the analysis of the results of our     studies for our <font color="blue">drug <font color="blue">candidates</font></font>:           •   we may not have the <font color="blue">financial resources</font> to <font color="blue">continue research</font> and     <font color="blue">development</font> of any of our <font color="blue">drug <font color="blue">candidates</font></font>; and                                           23     ______________________________________________________________________    [49]Table of <font color="blue">Contents       </font>  •   we may not be able to <font color="blue">enter into</font> collaborative arrangements relating     to any <font color="blue">drug candidate</font> subject to delay in <font color="blue">regulatory</font> filing</td>
    </tr>
    <tr>
      <td>Any of the following reasons, among others, could delay or suspend the     <font color="blue">completion</font> of our ongoing and <font color="blue">future studies</font>:           •   delays in <font color="blue">enrolling volunteers</font>;           •   <font color="blue">interruptions</font> in the <font color="blue">manufacturing</font> of our <font color="blue">drug <font color="blue">candidates</font></font> or other     delays in the delivery of materials required for the conduct of our studies;           •   lower than anticipated <font color="blue">retention rate</font> of volunteers in a trial;           •   <font color="blue">unfavorable efficacy</font> results;           •   serious side effects experienced <font color="blue">by study participants</font> relating to the     <font color="blue">drug candidate</font>;           •   new communications from <font color="blue">regulatory</font> agencies about how to conduct these     studies; or           •   failure to raise <font color="blue">additional</font> funds</td>
    </tr>
    <tr>
      <td>If the <font color="blue">manufacture</font>rs of our <font color="blue">drug <font color="blue">candidates</font></font> do not comply with current Good     Manufacturing Practices <font color="blue">regulations</font>, or cannot produce <font color="blue">sufficient quantities</font>     of our <font color="blue">drug <font color="blue">candidates</font></font> to <font color="blue">enable us</font> to continue our <font color="blue">development</font>, we will     <font color="blue">fall behind on</font> our business <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturers  </font>producing  our <font color="blue">drug <font color="blue">candidates</font></font> must follow current Good     Manufacturing  Practices  <font color="blue">regulations</font>  <font color="blue">enforced by</font> the FDA and foreign     <font color="blue">equivalents</font></td>
    </tr>
    <tr>
      <td>If a <font color="blue">manufacture</font>r of our <font color="blue">drug <font color="blue">candidates</font></font> does not conform to     <font color="blue">the Good Manufacturing Practices </font><font color="blue">regulations</font> and cannot be <font color="blue">brought up</font> to     such a standard, we will be required to find alternative <font color="blue">manufacture</font>rs that     do conform</td>
    </tr>
    <tr>
      <td>This may be a long and <font color="blue">difficult</font> process, and may delay our     ability  to  receive  FDA  or  foreign <font color="blue">regulatory</font> approval of our drug     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also rely on</font> our <font color="blue">manufacture</font>rs to <font color="blue">supply us with</font> a <font color="blue">sufficient quantity</font> of     our <font color="blue">drug <font color="blue">candidates</font></font> to conduct <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>If we have <font color="blue">difficult</font>y in the     future obtaining our required quantity and quality of supply, we could     experience <font color="blue">significant</font> delays in our <font color="blue">development</font> programs and <font color="blue">regulatory</font>     process</td>
    </tr>
    <tr>
      <td>Our ability to achieve any <font color="blue">significant</font> revenue may depend on our ability to     establish <font color="blue">effective</font> sales and <font color="blue">marketing capabilities</font></td>
    </tr>
    <tr>
      <td>Our efforts to date have <font color="blue">focused on</font> the <font color="blue">development</font> and <font color="blue">evaluation</font> of our     <font color="blue">drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>As we <font color="blue">continue preclinical</font> and <font color="blue">clinical studies</font> and seek to     <font color="blue">commercialize</font>  our  drug  <font color="blue">candidates</font>, we may need to build a sales and     <font color="blue">marketing infrastructure</font></td>
    </tr>
    <tr>
      <td>As a company, we have no experience in the sales     and  marketing  of  <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>If we fail to establish a     <font color="blue">sufficient marketing</font> and <font color="blue">sales force</font> or to make <font color="blue">alternative arrangements</font> to     have our <font color="blue">drug <font color="blue">candidates</font></font> marketed and <font color="blue">sold by others on attractive terms</font>, it     will impair our ability to <font color="blue">commercialize</font> our <font color="blue">drug <font color="blue">candidates</font></font> and to enter     new or <font color="blue">existing markets</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to <font color="blue">effective</font>ly enter these markets     would <font color="blue">materially</font> and <font color="blue">adversely</font> affect our ability to generate <font color="blue">significant</font>     revenues</td>
    </tr>
    <tr>
      <td>If we were to lose the services of Richard B Hollis, or fail to attract or     retain <font color="blue">qualified personnel</font> in the future, our business <font color="blue">objectives</font> would be     more <font color="blue">difficult</font> to implement, <font color="blue">adversely</font> affecting our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">successfully</font> implement our business <font color="blue">strategy depends highly</font>     upon  our  Chief  Executive  Officer,  Richard  B Hollis</td>
    </tr>
    <tr>
      <td>Hollis’ <font color="blue">services could impede</font> the <font color="blue">achievement</font> of our <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>We also     <font color="blue">highly depend on</font> our ability to hire and retain <font color="blue">qualified scientific</font> and     <font color="blue">technical personnel</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">competition</font> for these employees is intense</td>
    </tr>
    <tr>
      <td>Thus,     we may not be able to continue to hire and retain the <font color="blue">qualified personnel</font>     needed for our business</td>
    </tr>
    <tr>
      <td>Loss of the services of or the failure to recruit     <font color="blue">key scientific</font> and <font color="blue">technical personnel</font> could <font color="blue">adversely</font> affect our business,     operating results and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________    [50]Table of <font color="blue">Contents       </font>We <font color="blue">may face <font color="blue">product <font color="blue">liability</font></font></font> claims related to the use or misuse of our     <font color="blue">drug <font color="blue">candidates</font></font>, which may cause us to incur <font color="blue">significant</font> losses</td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently exposed</font> to the risk of <font color="blue">product <font color="blue">liability</font></font> claims due to     <font color="blue">administration</font> of our <font color="blue">drug <font color="blue">candidates</font></font> in <font color="blue">clinical trials</font>, since the use or     misuse of our <font color="blue">drug <font color="blue">candidates</font></font> during a clinical trial could <font color="blue">potentially</font>     result in injury or death</td>
    </tr>
    <tr>
      <td>If we are able to <font color="blue">commercialize</font> our products, we     will also be subject to the risk of losses in the future due to product     <font color="blue">liability</font> claims in the event that the use or misuse of our commercial     products  results  in injury or death</td>
    </tr>
    <tr>
      <td>We currently maintain <font color="blue">liability</font>     <font color="blue">insurance on</font> a claims-made basis</td>
    </tr>
    <tr>
      <td>Because we <font color="blue">cannot predict</font> the magnitude or     the number of claims that may be <font color="blue">brought against us</font> in the future, we do not     know whether the insurance policies’ coverage limits are adequate</td>
    </tr>
    <tr>
      <td>The     insurance is expensive, <font color="blue">difficult</font> to obtain and may not be available in the     future on acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>Any claims against us, regardless of     their merit, could substantially increase our costs and cause us to incur     <font color="blue">significant</font> losses</td>
    </tr>
    <tr>
      <td>Trading in our securities could be subject to <font color="blue">extreme price</font> <font color="blue">fluctuations</font>     that could <font color="blue">adversely</font> affect your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">market price</font>s</font> for securities of life sciences companies, particularly     those that are not profitable, are <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td><font color="blue">Publicized </font>events and     <font color="blue"><font color="blue">announcements</font> may</font> have a <font color="blue">significant</font> impact on the <font color="blue">market price</font> of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>For example:           •   biological or medical discoveries by <font color="blue">competitors</font>;           •   public concern about the safety of our <font color="blue">drug <font color="blue">candidates</font></font>;           •   delays in the conduct or analysis of our preclinical or clinical     studies;           •   unfavorable results <font color="blue">from preclinical</font> or <font color="blue">clinical studies</font>;           •   delays in obtaining or failure to obtain <font color="blue">purchase orders</font> of our drug     <font color="blue">candidates</font>;           •   <font color="blue">announcements</font> in the scientific and <font color="blue">research community</font>;           •   changes in the <font color="blue">potential commercial markets</font> for our <font color="blue">drug <font color="blue">candidates</font></font>;           •   unfavorable <font color="blue">development</font>s concerning patents or other <font color="blue">proprietary</font>     rights;           •   <font color="blue">unfavorable domestic</font> or foreign <font color="blue">regulatory</font> or <font color="blue">government</font>al     <font color="blue">development</font>s or actions; or           •   broader economic, industry and <font color="blue">market trends unrelated</font> to our     performance</td>
    </tr>
    <tr>
      <td>may have the effect of <font color="blue">temporarily</font> or <font color="blue">permanently driving down</font> the price of     our  common  stock</td>
    </tr>
    <tr>
      <td>In  addition,  the <font color="blue">stock market from</font> time to time     experiences <font color="blue">extreme price</font> and volume <font color="blue">fluctuations</font> which particularly affect     the <font color="blue"><font color="blue">market price</font>s</font> for emerging and life sciences companies, such as ours,     and which are often unrelated to the operating performance of the affected     companies</td>
    </tr>
    <tr>
      <td>These  broad market <font color="blue">fluctuations</font> may <font color="blue">adversely</font> affect the ability of a     stockholder to dispose of his shares at a price equal to or above the price     at which the shares were purchased</td>
    </tr>
    <tr>
      <td>In addition, in the past, following     periods  of  <font color="blue">volatility</font> in the <font color="blue">market price</font> of a company’s securities,     securities class-action <font color="blue">litigation</font> has <font color="blue">often been instituted against</font> that     company</td>
    </tr>
    <tr>
      <td>Any  <font color="blue">litigation</font>  against our company, including this type of     <font color="blue">litigation</font>,  could  result  in  substantial  costs  and a diversion of     <font color="blue">management</font>’s attention and resources, which could <font color="blue">materially</font> <font color="blue">adversely</font>     affect our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may be <font color="blue">delisted from</font> <font color="blue">The Nasdaq National Market</font>, which could <font color="blue">materially</font>     limit the <font color="blue">trading market</font> for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">common stock</font> is quoted on <font color="blue">The Nasdaq National Market</font></td>
    </tr>
    <tr>
      <td>In order to     continue to be included in <font color="blue">The Nasdaq National Market</font>, a company must meet     Nasdaq’s <font color="blue">maintenance criteria</font></td>
    </tr>
    <tr>
      <td>We may not be able to continue                                           25     ______________________________________________________________________    [51]Table of <font color="blue">Contents       </font>to  meet  these listing criteria</td>
    </tr>
    <tr>
      <td>Failure to meet Nasdaq’s maintenance     <font color="blue">criteria may</font> result in the delisting of our <font color="blue">common stock</font> from The Nasdaq     National Market</td>
    </tr>
    <tr>
      <td>If our <font color="blue">common stock</font> is delisted, in order to have our     <font color="blue">common stock</font> relisted on <font color="blue"><font color="blue">The Nasdaq National Market</font> </font>we would be required to     meet the criteria for initial listing, which are more <font color="blue">stringent than</font> the     <font color="blue">maintenance criteria</font></td>
    </tr>
    <tr>
      <td>Accordingly, if we were delisted we may not be able to     have our <font color="blue">common stock</font> relisted on <font color="blue">The Nasdaq National Market</font></td>
    </tr>
    <tr>
      <td>If our common     stock is <font color="blue">removed from listing on</font> <font color="blue">The Nasdaq National Market</font>, it may become     more <font color="blue">difficult</font> for us to <font color="blue">raise <font color="blue">funds through</font></font> the sale of our <font color="blue">common stock</font> or     <font color="blue">securities convertible into</font> our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Because <font color="blue">stock ownership</font> is <font color="blue">concentrated</font>, you and other <font color="blue">investors will</font> have     minimal influence on <font color="blue">stockholders</font>’ decisions</td>
    </tr>
    <tr>
      <td>Assuming that <font color="blue">outstanding warrants</font> and options have not <font color="blue">been exercised</font>,     Richard B Hollis, our Chief Executive Officer, owns <font color="blue">approximately</font> 11prca of     our  outstanding  common  stock as of <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Hollis exercises all of his <font color="blue">outstanding warrants</font> and options that vest     within 60 days of <font color="blue">December </font>31, 2005, Mr</td>
    </tr>
    <tr>
      <td>Hollis <font color="blue">would beneficially</font> own     <font color="blue">approximately</font> 18prca of our outstanding <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Hollis     </font>may  be able to <font color="blue">significant</font>ly influence our <font color="blue">management</font> and all matters     requiring <font color="blue">stockholder approval</font>, including the election of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font><font color="blue">concentration</font>  of  ownership  may  also have the effect of delaying or     preventing a change in control of our company</td>
    </tr>
    <tr>
      <td><font color="blue">Substantial </font>sales of our stock may impact the <font color="blue">market price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>Future sales of substantial amounts of our <font color="blue">common stock</font>, including shares     that we <font color="blue">may issue upon exercise</font> of options and warrants, could <font color="blue">adversely</font>     affect the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Further, if we raise <font color="blue">additional</font>     <font color="blue">funds through</font> the issuance of <font color="blue">common stock</font> or <font color="blue">securities convertible into</font> or     exercisable for <font color="blue">common stock</font>, the <font color="blue">percentage ownership</font> of our <font color="blue">stockholders</font>     will be reduced and the price of our <font color="blue">common stock</font> may fall</td>
    </tr>
    <tr>
      <td>Issuing <font color="blue"><font color="blue">preferred stock</font> with rights senior</font> to those of our <font color="blue">common stock</font>     could <font color="blue">adversely</font> affect holders of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">charter documents give</font> our board of <font color="blue">directors</font> the authority to issue     shares of <font color="blue"><font color="blue">preferred stock</font> without</font> a vote or <font color="blue">action by</font> our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">board also</font> has the authority to determine the terms of <font color="blue">preferred stock</font>,     including  price, preferences and <font color="blue">voting rights</font></td>
    </tr>
    <tr>
      <td>The rights granted to     holders of <font color="blue">preferred stock</font> may <font color="blue">adversely</font> affect the rights of holders of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>For example, a series of <font color="blue">preferred stock</font> may be granted the     right to receive a liquidation preference—a pre-set <font color="blue">distribution</font> in the     event  of  a  liquidation—that  would  reduce the <font color="blue">amount available</font> for     <font color="blue">distribution</font>  to holders of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, the issuance of     <font color="blue">preferred stock</font> could make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire a     majority of our <font color="blue">outstanding voting stock</font></td>
    </tr>
    <tr>
      <td>As a result, <font color="blue">common stock</font>holders     could be prevented from <font color="blue">participating</font> in <font color="blue">transactions</font> that would offer an     optimal price for their shares</td>
    </tr>
  </tbody>
</table>